{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:03:32Z","timestamp":1695009812707},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Although angiotensin-converting enzyme II inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) improve chronic heart failure (HF) outcomes, their potential harms and benefits in acute HF (AHF) is less clear.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Study Question:<\/jats:title>\n            <jats:p>We explored the relationship between ACEI or ARB plasma concentrations among patients with AHF with in-hospital change in estimated glomerular filtration rate (eGFR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Data Sources and Study Design:<\/jats:title>\n            <jats:p>From August 2016\u2013June 2017, patients with AHF prescribed an outpatient ACEI or ARB were enrolled before AHF treatment. All patients were given twice their home dose of diuretic intravenously and received clinical care at the discretion of the medical team. Of 61 patients in the parent study, saved plasma from 34 who were prescribed an outpatient ACEI or ARB was included in this substudy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Measures and Outcomes:<\/jats:title>\n            <jats:p>Liquid chromatography\u2013tandem mass spectrometry was performed to assess ACEI or ARB plasma concentrations before AHF treatment. Change in eGFR was computed using the Chronic Kidney Disease Epidemiology Collaboration equation, which adjusts for age, sex, and race; diuretic dose and enrollment eGFR were used to adjust for HF severity. Multiple linear regression adjusting for enrollment eGFR and diuretic dose was performed to examine the relationship between drug concentration (undetectable\/low vs. in\/above-range) and in-hospital change in eGFR.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of 34 patients with AHF, median age was 63 years (interquartile range, 58\u201378 years), 19 (55.9%) were women, median eGFR at enrollment was 55.6 mL\/min (interquartile range, 35.2\u201375.3 mL\/min), and for 11 (32.4%), no ACEI or ARB was detectable in plasma. Medication concentrations in- or above-reference range were associated with in-hospital decrease in eGFR of 8.3 mL\/min (95% confidence interval, 15.3\u20131.3 mL\/min decrease), after adjusting for enrollment eGFR and diuretic treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Bioanalytical assessment of medication levels may be useful to guide in-hospital ACEI and ARB therapy for patients with AHF.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mjt.0000000000000990","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T09:03:57Z","timestamp":1576055037000},"page":"e366-e370","source":"Crossref","is-referenced-by-count":0,"title":["Bioanalytical Assessment of Plasma Concentrations of Angiotensin-Converting Enzyme II Inhibitors and Angiotensin Receptor Blockers: A Pilot Study Among Patients Hospitalized With Acute Heart Failure"],"prefix":"10.1097","volume":"27","author":[{"given":"Candace D.","family":"McNaughton","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, Vanderbilt University Medical Center, Tennessee Valley Healthcare System VA Medical Center, Nashville, TN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Vanderbilt University Medical Center, Tennessee Valley Healthcare System VA Medical Center, Nashville, TN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JoAnn","family":"Lindenfeld","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Morrison","sequence":"additional","affiliation":[{"name":"Precera Bioscience, Inc, Brentwood, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Scott","family":"Daniels","sequence":"additional","affiliation":[{"name":"Precera Bioscience, Inc, Brentwood, TN."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,7]]},"reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation."},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1053\/j.ackd.2008.04.002","article-title":"Acute kidney injury: definitions and new paradigms","volume":"15","author":"Endre","year":"2008","journal-title":"Adv Chronic Kidney Dis."},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/hc4101.096153","article-title":"Council on the kidney in cardiovascular D, the council for high blood pressure research of the American Heart A. renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association","volume":"104","author":"Schoolwerth","year":"2001","journal-title":"Circulation."},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccc.2015.06.006","article-title":"A clinical approach to the acute cardiorenal syndrome","volume":"31","author":"Jentzer","year":"2015","journal-title":"Crit Care Clin."},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"e003588","DOI":"10.1161\/CIRCHEARTFAILURE.116.003588","article-title":"Renin-angiotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction: a meta-analysis of published study data","volume":"10","author":"Beldhuis","year":"2017","journal-title":"Circ Heart Fail."},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1097\/CCM.0000000000000404","article-title":"When cardiac failure, kidney dysfunction, and kidney injury intersect in acute conditions: the case of cardiorenal syndrome","volume":"42","author":"Legrand","year":"2014","journal-title":"Crit Care Med."},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ehf2.12368","article-title":"Early urine electrolyte patterns in patients with acute heart failure","volume":"6","author":"Collins","year":"2019","journal-title":"ESC Heart Fail."},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"e184196","DOI":"10.1001\/jamanetworkopen.2018.4196","article-title":"Assessment of patient medication adherence, medical record accuracy, and medication blood concentrations for prescription and over-the-counter medications","volume":"1","author":"Sutherland","year":"2018","journal-title":"JAMA Netw Open."},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2165\/00003088-199834060-00003","article-title":"Clinical pharmacokinetics of vasodilators. Part I","volume":"34","author":"Kirsten","year":"1998","journal-title":"Clin Pharmacokinet."},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/106002809603000110","article-title":"Adverse effects of the angiotensin-converting enzyme inhibitors","volume":"30","author":"Alderman","year":"1996","journal-title":"Ann Pharmacother."},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1023\/A:1009935116877","article-title":"Drug levels: therapeutic and toxic serum\/plasma concentrations of common drugs","volume":"15","author":"Regenthal","year":"1999","journal-title":"J Clin Monit Comput."},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","article-title":"Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions","volume":"55","author":"Levey","year":"2010","journal-title":"Am J Kidney Dis."},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/clpt.1983.154","article-title":"Bumetanide and furosemide","volume":"34","author":"Brater","year":"1983","journal-title":"Clin Pharmacol Ther."},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/oxfordjournals.aje.a009532","article-title":"Describing data requires no adjustment for multiple comparisons: a reply from Savitz and Olshan","volume":"147","author":"Savitz","year":"1998","journal-title":"Am J Epidemiol."},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1161\/CIRCHEARTFAILURE.111.963256","article-title":"Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction","volume":"4","author":"Testani","year":"2011","journal-title":"Circ Heart Fail."},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s00134-018-5160-6","article-title":"Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury","volume":"44","author":"Gayat","year":"2018","journal-title":"Intensive Care Med."},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ijcard.2014.07.085","article-title":"Management of oral chronic pharmacotherapy in patients hospitalized for acute decompensated heart failure","volume":"176","author":"Piepoli","year":"2014","journal-title":"Int J Cardiol."}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0000000000000990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T04:12:12Z","timestamp":1694923932000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0000000000000990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":17,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0000000000000990","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,10]]}}}